28 Aug 2024

Xbrane Biopharma releases Interim Report for January-June 2024

23 Aug 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2024 on August 28, 2024

12 Aug 2024

Xbrane provides update on the ongoing out-licensing of Xdivane™ (nivolumab biosimilar candidate) and XB003 (Cimzia® biosimilar candidate) and its financial position

01 Aug 2024

Xbrane to regain full rights to BIIB801, a proposed biosimilar referencing CIMZIA®

16 Jul 2024

Xbrane provides update on its development portfolio

08 Jul 2024

Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate

22 May 2024

Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® – and run an active partnering process

16 May 2024

Xbrane Biopharma releases Interim Report for January-March 2024

13 May 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024